Related Experiment Video
Updated: Aug 11, 2026
19:34
Cellular Toxicity of Nanogenomedicine in MCF-7 Cell Line: MTT assay
Published on: April 3, 2009
Mitozolomide activity on human cancer cells in vitro
British Journal of Cancer
|December 1, 1986
Summary
Mitozolomide shows cell cycle effects on melanoma and ovarian cancer cells, but primary ovarian cancers appear resistant. Further research is needed to understand mitozolomide
Area of Science:
- Oncology
- Pharmacology
- Cell Biology
Background:
- Mitozolomide is a novel agent investigated for anti-cancer properties.
- Carmustine (BCNU) is a known chemotherapeutic agent used for comparison.
Purpose of the Study:
- To compare the effects of mitozolomide and BCNU on M14 human melanoma and SW626 human ovarian cancer cell lines.
- To investigate the susceptibility of primary human ovarian cancer cells to mitozolomide.
Main Methods:
- Cell growth inhibition assays.
- Analysis of [3H]-thymidine incorporation.
- Flow cytometry for cell cycle analysis.
- Primary cell culture of human ovarian cancers.
Main Results:
- Mitozolomide exhibited growth inhibitory effects and induced cell cycle perturbation in both cell lines.
- Mitozolomide caused accumulation of cells in S-middle and late-G2-M phases, while BCNU caused a block in late-G2-M.
- Only one of 16 primary ovarian cancer cultures showed sensitivity to mitozolomide.
Conclusions:
- Mitozolomide demonstrates differential cell cycle effects compared to BCNU.
- Primary human ovarian cancer cells may exhibit resistance to mitozolomide at pharmacologically relevant concentrations.
